ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recombinant Protein Vaccine Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-17R10582
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global and United States Recombinant Protein Vaccine Market Report Forecast 2022 2028
BUY CHAPTERS

Global Recombinant Protein Vaccine Market Research Report 2025

Code: QYRE-Auto-17R10582
Report
July 2025
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Novavax Inc
Medicago
Pukang Biologic Technology
Johnson & Johnson
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Johnson & Johnson

Recombinant Protein Vaccine Market Size

The global pharmaceutical market is 1475 billion US$ in 2022, growing at a CAGR of 5% during the next six years.

Recombinant Protein Vaccine Market

Recombinant Protein Vaccine Market

The global market for Recombinant Protein Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Recombinant Protein Vaccine refers to the vaccines manufactured using recombinant DNA technology
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion US$ in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Protein Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Protein Vaccine.
The Recombinant Protein Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Protein Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Protein Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Recombinant Protein Vaccine Market Report

Report Metric Details
Report Name Recombinant Protein Vaccine Market
CAGR 5%
Segment by Type
Segment by Application
  • Human
  • Animal
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences, Novavax, Medicago, Pukang Biologic Technology, Johnson & Johnson, Clover Biopharmaceuticals, Suzhou Yuzhibo Biotechnology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Recombinant Protein Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Recombinant Protein Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Recombinant Protein Vaccine Market report?

Ans: The main players in the Recombinant Protein Vaccine Market are Merck, GSK, Sanofi, Zoties, Elanco, Boehringer-Ingelheim, Indian Immunologicals, Plumbline Life Sciences, Novavax, Medicago, Pukang Biologic Technology, Johnson & Johnson, Clover Biopharmaceuticals, Suzhou Yuzhibo Biotechnology

What are the Application segmentation covered in the Recombinant Protein Vaccine Market report?

Ans: The Applications covered in the Recombinant Protein Vaccine Market report are Human, Animal

What are the Type segmentation covered in the Recombinant Protein Vaccine Market report?

Ans: The Types covered in the Recombinant Protein Vaccine Market report are Bacterial Cells Culture, Mammalian Cells Culture

Recommended Reports

Recombinant & Engineered Vaccines

General & Pediatric Vaccines

Inactivated & Specialized Vaccines

1 Recombinant Protein Vaccine Market Overview
1.1 Product Definition
1.2 Recombinant Protein Vaccine by Type
1.2.1 Global Recombinant Protein Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Bacterial Cells Culture
1.2.3 Mammalian Cells Culture
1.3 Recombinant Protein Vaccine by Application
1.3.1 Global Recombinant Protein Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Human
1.3.3 Animal
1.4 Global Recombinant Protein Vaccine Market Size Estimates and Forecasts
1.4.1 Global Recombinant Protein Vaccine Revenue 2020-2031
1.4.2 Global Recombinant Protein Vaccine Sales 2020-2031
1.4.3 Global Recombinant Protein Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Recombinant Protein Vaccine Market Competition by Manufacturers
2.1 Global Recombinant Protein Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Recombinant Protein Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Recombinant Protein Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Recombinant Protein Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Protein Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Protein Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Protein Vaccine, Date of Enter into This Industry
2.8 Global Recombinant Protein Vaccine Market Competitive Situation and Trends
2.8.1 Global Recombinant Protein Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Protein Vaccine Players Market Share by Revenue
2.8.3 Global Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Protein Vaccine Market Scenario by Region
3.1 Global Recombinant Protein Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Recombinant Protein Vaccine Sales by Region: 2020-2031
3.2.1 Global Recombinant Protein Vaccine Sales by Region: 2020-2025
3.2.2 Global Recombinant Protein Vaccine Sales by Region: 2026-2031
3.3 Global Recombinant Protein Vaccine Revenue by Region: 2020-2031
3.3.1 Global Recombinant Protein Vaccine Revenue by Region: 2020-2025
3.3.2 Global Recombinant Protein Vaccine Revenue by Region: 2026-2031
3.4 North America Recombinant Protein Vaccine Market Facts & Figures by Country
3.4.1 North America Recombinant Protein Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Recombinant Protein Vaccine Sales by Country (2020-2031)
3.4.3 North America Recombinant Protein Vaccine Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Recombinant Protein Vaccine Market Facts & Figures by Country
3.5.1 Europe Recombinant Protein Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Recombinant Protein Vaccine Sales by Country (2020-2031)
3.5.3 Europe Recombinant Protein Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Protein Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Protein Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Recombinant Protein Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Recombinant Protein Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Recombinant Protein Vaccine Market Facts & Figures by Country
3.7.1 Latin America Recombinant Protein Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Recombinant Protein Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Recombinant Protein Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Protein Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Protein Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Recombinant Protein Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Recombinant Protein Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Recombinant Protein Vaccine Sales by Type (2020-2031)
4.1.1 Global Recombinant Protein Vaccine Sales by Type (2020-2025)
4.1.2 Global Recombinant Protein Vaccine Sales by Type (2026-2031)
4.1.3 Global Recombinant Protein Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Protein Vaccine Revenue by Type (2020-2031)
4.2.1 Global Recombinant Protein Vaccine Revenue by Type (2020-2025)
4.2.2 Global Recombinant Protein Vaccine Revenue by Type (2026-2031)
4.2.3 Global Recombinant Protein Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Recombinant Protein Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Recombinant Protein Vaccine Sales by Application (2020-2031)
5.1.1 Global Recombinant Protein Vaccine Sales by Application (2020-2025)
5.1.2 Global Recombinant Protein Vaccine Sales by Application (2026-2031)
5.1.3 Global Recombinant Protein Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Recombinant Protein Vaccine Revenue by Application (2020-2031)
5.2.1 Global Recombinant Protein Vaccine Revenue by Application (2020-2025)
5.2.2 Global Recombinant Protein Vaccine Revenue by Application (2026-2031)
5.2.3 Global Recombinant Protein Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Recombinant Protein Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Company Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Merck Recombinant Protein Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Recombinant Protein Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Company Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Sanofi Recombinant Protein Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Zoties
6.4.1 Zoties Company Information
6.4.2 Zoties Description and Business Overview
6.4.3 Zoties Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Zoties Recombinant Protein Vaccine Product Portfolio
6.4.5 Zoties Recent Developments/Updates
6.5 Elanco
6.5.1 Elanco Company Information
6.5.2 Elanco Description and Business Overview
6.5.3 Elanco Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Elanco Recombinant Protein Vaccine Product Portfolio
6.5.5 Elanco Recent Developments/Updates
6.6 Boehringer-Ingelheim
6.6.1 Boehringer-Ingelheim Company Information
6.6.2 Boehringer-Ingelheim Description and Business Overview
6.6.3 Boehringer-Ingelheim Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Boehringer-Ingelheim Recombinant Protein Vaccine Product Portfolio
6.6.5 Boehringer-Ingelheim Recent Developments/Updates
6.7 Indian Immunologicals
6.7.1 Indian Immunologicals Company Information
6.7.2 Indian Immunologicals Description and Business Overview
6.7.3 Indian Immunologicals Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Indian Immunologicals Recombinant Protein Vaccine Product Portfolio
6.7.5 Indian Immunologicals Recent Developments/Updates
6.8 Plumbline Life Sciences
6.8.1 Plumbline Life Sciences Company Information
6.8.2 Plumbline Life Sciences Description and Business Overview
6.8.3 Plumbline Life Sciences Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Plumbline Life Sciences Recombinant Protein Vaccine Product Portfolio
6.8.5 Plumbline Life Sciences Recent Developments/Updates
6.9 Novavax
6.9.1 Novavax Company Information
6.9.2 Novavax Description and Business Overview
6.9.3 Novavax Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Novavax Recombinant Protein Vaccine Product Portfolio
6.9.5 Novavax Recent Developments/Updates
6.10 Medicago
6.10.1 Medicago Company Information
6.10.2 Medicago Description and Business Overview
6.10.3 Medicago Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Medicago Recombinant Protein Vaccine Product Portfolio
6.10.5 Medicago Recent Developments/Updates
6.11 Pukang Biologic Technology
6.11.1 Pukang Biologic Technology Company Information
6.11.2 Pukang Biologic Technology Description and Business Overview
6.11.3 Pukang Biologic Technology Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Pukang Biologic Technology Recombinant Protein Vaccine Product Portfolio
6.11.5 Pukang Biologic Technology Recent Developments/Updates
6.12 Johnson & Johnson
6.12.1 Johnson & Johnson Company Information
6.12.2 Johnson & Johnson Description and Business Overview
6.12.3 Johnson & Johnson Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Johnson & Johnson Recombinant Protein Vaccine Product Portfolio
6.12.5 Johnson & Johnson Recent Developments/Updates
6.13 Clover Biopharmaceuticals
6.13.1 Clover Biopharmaceuticals Company Information
6.13.2 Clover Biopharmaceuticals Description and Business Overview
6.13.3 Clover Biopharmaceuticals Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Clover Biopharmaceuticals Recombinant Protein Vaccine Product Portfolio
6.13.5 Clover Biopharmaceuticals Recent Developments/Updates
6.14 Suzhou Yuzhibo Biotechnology
6.14.1 Suzhou Yuzhibo Biotechnology Company Information
6.14.2 Suzhou Yuzhibo Biotechnology Description and Business Overview
6.14.3 Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Product Portfolio
6.14.5 Suzhou Yuzhibo Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Protein Vaccine Industry Chain Analysis
7.2 Recombinant Protein Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Protein Vaccine Production Mode & Process Analysis
7.4 Recombinant Protein Vaccine Sales and Marketing
7.4.1 Recombinant Protein Vaccine Sales Channels
7.4.2 Recombinant Protein Vaccine Distributors
7.5 Recombinant Protein Vaccine Customer Analysis
8 Recombinant Protein Vaccine Market Dynamics
8.1 Recombinant Protein Vaccine Industry Trends
8.2 Recombinant Protein Vaccine Market Drivers
8.3 Recombinant Protein Vaccine Market Challenges
8.4 Recombinant Protein Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Merck
GSK
Sanofi
Zoties
Elanco
Boehringer Ingelheim
Indian Immunologicals
Plumbline Life Sciences
Novavax Inc
Medicago
Pukang Biologic Technology
Johnson & Johnson
Clover Biopharmaceuticals
Suzhou Yuzhibo Biotechnology
Johnson & Johnson
List of Tables
 Table 1. Global Recombinant Protein Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Recombinant Protein Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Recombinant Protein Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Recombinant Protein Vaccine Sales (K Doses) of Key Manufacturers (2020-2025)
 Table 5. Global Recombinant Protein Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Recombinant Protein Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Recombinant Protein Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Recombinant Protein Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Recombinant Protein Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Recombinant Protein Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Recombinant Protein Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Recombinant Protein Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Recombinant Protein Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Protein Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Recombinant Protein Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Recombinant Protein Vaccine Sales by Region (2020-2025) & (K Doses)
 Table 18. Global Recombinant Protein Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Recombinant Protein Vaccine Sales by Region (2026-2031) & (K Doses)
 Table 20. Global Recombinant Protein Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Recombinant Protein Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Recombinant Protein Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Recombinant Protein Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Recombinant Protein Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Recombinant Protein Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Recombinant Protein Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 27. North America Recombinant Protein Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 28. North America Recombinant Protein Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Recombinant Protein Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Recombinant Protein Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Recombinant Protein Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 32. Europe Recombinant Protein Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 33. Europe Recombinant Protein Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Recombinant Protein Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Recombinant Protein Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Recombinant Protein Vaccine Sales by Region (2020-2025) & (K Doses)
 Table 37. Asia Pacific Recombinant Protein Vaccine Sales by Region (2026-2031) & (K Doses)
 Table 38. Asia Pacific Recombinant Protein Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Recombinant Protein Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Recombinant Protein Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Recombinant Protein Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 42. Latin America Recombinant Protein Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 43. Latin America Recombinant Protein Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Recombinant Protein Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Recombinant Protein Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Recombinant Protein Vaccine Sales by Country (2020-2025) & (K Doses)
 Table 47. Middle East and Africa Recombinant Protein Vaccine Sales by Country (2026-2031) & (K Doses)
 Table 48. Middle East and Africa Recombinant Protein Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Recombinant Protein Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Recombinant Protein Vaccine Sales (K Doses) by Type (2020-2025)
 Table 51. Global Recombinant Protein Vaccine Sales (K Doses) by Type (2026-2031)
 Table 52. Global Recombinant Protein Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Recombinant Protein Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Recombinant Protein Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Recombinant Protein Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Recombinant Protein Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Recombinant Protein Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Recombinant Protein Vaccine Price (US$/Dose) by Type (2020-2025)
 Table 59. Global Recombinant Protein Vaccine Price (US$/Dose) by Type (2026-2031)
 Table 60. Global Recombinant Protein Vaccine Sales (K Doses) by Application (2020-2025)
 Table 61. Global Recombinant Protein Vaccine Sales (K Doses) by Application (2026-2031)
 Table 62. Global Recombinant Protein Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Recombinant Protein Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Recombinant Protein Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Recombinant Protein Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Recombinant Protein Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Recombinant Protein Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Recombinant Protein Vaccine Price (US$/Dose) by Application (2020-2025)
 Table 69. Global Recombinant Protein Vaccine Price (US$/Dose) by Application (2026-2031)
 Table 70. Merck Company Information
 Table 71. Merck Description and Business Overview
 Table 72. Merck Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 73. Merck Recombinant Protein Vaccine Product
 Table 74. Merck Recent Developments/Updates
 Table 75. GSK Company Information
 Table 76. GSK Description and Business Overview
 Table 77. GSK Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 78. GSK Recombinant Protein Vaccine Product
 Table 79. GSK Recent Developments/Updates
 Table 80. Sanofi Company Information
 Table 81. Sanofi Description and Business Overview
 Table 82. Sanofi Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 83. Sanofi Recombinant Protein Vaccine Product
 Table 84. Sanofi Recent Developments/Updates
 Table 85. Zoties Company Information
 Table 86. Zoties Description and Business Overview
 Table 87. Zoties Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 88. Zoties Recombinant Protein Vaccine Product
 Table 89. Zoties Recent Developments/Updates
 Table 90. Elanco Company Information
 Table 91. Elanco Description and Business Overview
 Table 92. Elanco Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 93. Elanco Recombinant Protein Vaccine Product
 Table 94. Elanco Recent Developments/Updates
 Table 95. Boehringer-Ingelheim Company Information
 Table 96. Boehringer-Ingelheim Description and Business Overview
 Table 97. Boehringer-Ingelheim Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 98. Boehringer-Ingelheim Recombinant Protein Vaccine Product
 Table 99. Boehringer-Ingelheim Recent Developments/Updates
 Table 100. Indian Immunologicals Company Information
 Table 101. Indian Immunologicals Description and Business Overview
 Table 102. Indian Immunologicals Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 103. Indian Immunologicals Recombinant Protein Vaccine Product
 Table 104. Indian Immunologicals Recent Developments/Updates
 Table 105. Plumbline Life Sciences Company Information
 Table 106. Plumbline Life Sciences Description and Business Overview
 Table 107. Plumbline Life Sciences Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 108. Plumbline Life Sciences Recombinant Protein Vaccine Product
 Table 109. Plumbline Life Sciences Recent Developments/Updates
 Table 110. Novavax Company Information
 Table 111. Novavax Description and Business Overview
 Table 112. Novavax Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 113. Novavax Recombinant Protein Vaccine Product
 Table 114. Novavax Recent Developments/Updates
 Table 115. Medicago Company Information
 Table 116. Medicago Description and Business Overview
 Table 117. Medicago Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 118. Medicago Recombinant Protein Vaccine Product
 Table 119. Medicago Recent Developments/Updates
 Table 120. Pukang Biologic Technology Company Information
 Table 121. Pukang Biologic Technology Description and Business Overview
 Table 122. Pukang Biologic Technology Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 123. Pukang Biologic Technology Recombinant Protein Vaccine Product
 Table 124. Pukang Biologic Technology Recent Developments/Updates
 Table 125. Johnson & Johnson Company Information
 Table 126. Johnson & Johnson Description and Business Overview
 Table 127. Johnson & Johnson Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 128. Johnson & Johnson Recombinant Protein Vaccine Product
 Table 129. Johnson & Johnson Recent Developments/Updates
 Table 130. Clover Biopharmaceuticals Company Information
 Table 131. Clover Biopharmaceuticals Description and Business Overview
 Table 132. Clover Biopharmaceuticals Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 133. Clover Biopharmaceuticals Recombinant Protein Vaccine Product
 Table 134. Clover Biopharmaceuticals Recent Developments/Updates
 Table 135. Suzhou Yuzhibo Biotechnology Company Information
 Table 136. Suzhou Yuzhibo Biotechnology Description and Business Overview
 Table 137. Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 138. Suzhou Yuzhibo Biotechnology Recombinant Protein Vaccine Product
 Table 139. Suzhou Yuzhibo Biotechnology Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Recombinant Protein Vaccine Distributors List
 Table 143. Recombinant Protein Vaccine Customers List
 Table 144. Recombinant Protein Vaccine Market Trends
 Table 145. Recombinant Protein Vaccine Market Drivers
 Table 146. Recombinant Protein Vaccine Market Challenges
 Table 147. Recombinant Protein Vaccine Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Recombinant Protein Vaccine
 Figure 2. Global Recombinant Protein Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Recombinant Protein Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Bacterial Cells Culture Product Picture
 Figure 5. Mammalian Cells Culture Product Picture
 Figure 6. Global Recombinant Protein Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Recombinant Protein Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Human
 Figure 9. Animal
 Figure 10. Global Recombinant Protein Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Recombinant Protein Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Recombinant Protein Vaccine Sales (2020-2031) & (K Doses)
 Figure 13. Global Recombinant Protein Vaccine Average Price (US$/Dose) & (2020-2031)
 Figure 14. Recombinant Protein Vaccine Report Years Considered
 Figure 15. Recombinant Protein Vaccine Sales Share by Manufacturers in 2024
 Figure 16. Global Recombinant Protein Vaccine Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Recombinant Protein Vaccine Players: Market Share by Revenue in Recombinant Protein Vaccine in 2024
 Figure 18. Recombinant Protein Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Recombinant Protein Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Recombinant Protein Vaccine Sales Market Share by Country (2020-2031)
 Figure 21. North America Recombinant Protein Vaccine Revenue Market Share by Country (2020-2031)
 Figure 22. U.S. Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Recombinant Protein Vaccine Sales Market Share by Country (2020-2031)
 Figure 25. Europe Recombinant Protein Vaccine Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Recombinant Protein Vaccine Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Recombinant Protein Vaccine Revenue Market Share by Region (2020-2031)
 Figure 33. China Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Taiwan Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Indonesia Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Thailand Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Malaysia Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Philippines Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Recombinant Protein Vaccine Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Recombinant Protein Vaccine Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Recombinant Protein Vaccine Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Recombinant Protein Vaccine Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. U.A.E Recombinant Protein Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Recombinant Protein Vaccine by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Recombinant Protein Vaccine by Type (2020-2031)
 Figure 55. Global Recombinant Protein Vaccine Price (US$/Dose) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Recombinant Protein Vaccine by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Recombinant Protein Vaccine by Application (2020-2031)
 Figure 58. Global Recombinant Protein Vaccine Price (US$/Dose) by Application (2020-2031)
 Figure 59. Recombinant Protein Vaccine Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Recombinant Protein Therapeutics Market
Global Genetic Vaccine Market Insights Forecast to 2030
Global Recombinant Protein Reagents Market Research Report 2025
Global Recombinant Protein Service Market Research Report 2025
Global Recombinant Protein Drug R D Market Research Report 2024
Recombinant Protein Drugs Market
Therapeutic Recombinant Protein Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant DNA Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Protein Expression and Purification Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Therapeutic Protein Market Research Report 2025
Global DNA Vaccines Market Insights Forecast to 2030
Global Recombinant Plasma Protein Therapeutics Market Insights Forecast to 2030
Global Protein Expression Technology Market Research Report 2024
Global Recombinant Growth Factors Market Research Report 2025
Global Biopharmaceutical and Vaccines Market Research Report 2024
Global Recombinant Factor Products Market Research Report 2024
Global Recombinant Plasma Proteins Market Insights Forecast to 2030
Global Recombinant Glycosylated Protein Market Research Report 2025
Global Gene Engineered Subunit Vaccine Market Research Report 2024
Recombinant Parvovirus Antigens Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions